Cyclica Receives CAD$2.4M Grant for a Multi-targeted Drug Discovery Program to Advance Non-Hormonal Contraceptive Medicines

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

Cyclica Inc., a neo-biotech that is unlocking the protein universe to discover the medicines of tomorrow, is developing new, non-hormonal contraceptives for low-data biological protein targets with support from a grant from the Bill & Melinda Gates Foundation.

The CAD$2.4M grant enables Cyclica to apply its validated, AI-enabled drug discovery platform towards the discovery of expanded contraceptive options that can give women and girls the ability to better plan their families and their futures.

Cyclica is an OBIO® member and presented at the OBIO Investment Summit.

Arsheen Kaur
Previous

OBIO® Appoints New Chair & Board Members to Plan for the Future of the Healthcare Innovation Sector
Next

Bruker Announces Agreement to Acquire Neurescence Inc., Bolstering Neuroscience Research Portfolio